US Edition
News from Endpoints News
We’ve assigned a rating of Unknown factuality to Endpoints News. You can read more about how we’ve determined Endpoints News’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Endpoints News News
Seoul · SeoulA South Korean biotech working on multi-specific autoimmune disease treatments is looking to make a leap into the US.
Curogen, based in Seoul and backed by local investors, announced Monday that it plans to open ...See the Story
Korean startup Curogen seeks global expansion, new funding to back autoimmune drugs
Eli Lilly · IndianapolisCHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...See the Story
Phase 3 or bust: Why Lilly won't run mid-stage cancer trials
Breast Cancer(MedPage Today) -- CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09...See the Story
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
100% Center coverage: 2 sources
